$BIIB Recent Headlines Investors gloss over Bi
Post# of 144878
Posted On: 04/27/2014 11:36:16 AM
$BIIB Recent Headlines
Investors gloss over Biogen earnings miss and focus on MS drug sales 2:23 p.m. April 23, 2014 - blogs.marketwatch.com
Scouring the moonscape for leading stocks 3:01 p.m. April 22, 2014 - The Trading Deck
Apple, Microsoft are not the keys to this week’s news 7:00 a.m. April 22, 2014 - Marek Fuchs
Long view on stocks is best during weak earnings season 6:00 a.m. April 20, 2014 - Wallace Witkowski
Biotech misses out on Nasdaq rally, sinks further into bear ground 4:58 p.m. April 14, 2014 - blogs.marketwatch.com
Herbalife sinks on probe fears; Zoe’s surges on debut 4:36 p.m. April 11, 2014 - Ben Eisen
Stocks fall for 3rd day in row; S&P 500 down for year again: stock market live blog recap 4:11 p.m. April 7, 2014 - blogs.marketwatch.com
Biotech bargain? 11:43 a.m. April 1, 2014 - The Trading Deck
Facebook, Biogen, Cal-Maine are stocks to watch 5:21 a.m. March 31, 2014 - Victor Reklaitis
U.S. stocks end week with losses 7:17 p.m. March 28, 2014 - Anora Mahmudova
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - blogs.marketwatch.com
U.S. stocks fall; Nasdaq skids 1.2% 4:40 p.m. March 24, 2014 - Anora Mahmudova
Biotech has second straight sell-off; sector mutual funds take it on chin 10:40 a.m. March 24, 2014 - blogs.marketwatch.com
First Solar extends winning streak; Symantec plunges 3:06 p.m. March 21, 2014 - Ben Eisen
Investors let air out of biotech amid overheating, pricing concerns 1:42 p.m. March 21, 2014 - blogs.marketwatch.com
U.S. stocks rise; S&P 500 positive for the year 4:39 p.m. March 17, 2014 - Anora Mahmudova
Yahoo gains on Alibaba IPO; Plug Power loses momentum 4:17 p.m. March 17, 2014 - Saumya Vaishampayan
Keurig Green Mountain added to S&P 500 index 9:56 a.m. March 15, 2014 - MarketWatch.com
From every angle, technicals point to richer stocks 2:25 p.m. March 11, 2014 - The Trading Deck
Disappointments? Think Opportunities; Miracle Drug May Be Ailing Gilead: Jim Cramer's Best Blogs 6:00 a.m. April 26, 2014 - TheStreet.com
Amgen Blazed Biotech Trail, Earned 165,233% Reward 5:51 p.m. April 25, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: EBAY, AXP, BIIB 3:59 p.m. April 25, 2014 - TheStreet.com
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog 5:50 p.m. April 24, 2014 - Zacks.com
Gilead, Alexion, Biogen, Or Celgene: 1 Mindboggling Metric Identifies The Best Value! 4:57 p.m. April 24, 2014 - Seeking Alpha
3 Drugs Stocks Dragging The Industry Down 1:03 p.m. April 24, 2014 - TheStreet.com
Stock Market News for April 24, 2014 - Market News 10:06 a.m. April 24, 2014 - Zacks.com
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape 8:49 a.m. April 24, 2014 - Zacks.com
Prothena Corporation plc (PRTA) Worth Watching: Stock Rises 9.5% - Tale of the Tape 8:44 a.m. April 24, 2014 - Zacks.com
Biogen partners with Quintiles to beef up its clinical development processes 8:18 a.m. April 24, 2014 - Seeking Alpha
Biogen Idec Inc. (BIIB): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. April 24, 2014 - Zacks.com
Quintiles, Biogen Idec Announce Comprehensive Clinical Development Partnership 7:01 a.m. April 24, 2014 - benzinga.com
After the Apple Split, Five More Bull Market Stock Splits Needed 6:39 a.m. April 24, 2014 - 247WallSt.com
Biogen Idec's CEO Discusses Q1 2014 Earnings Results - Earnings Call Transcript 10:54 p.m. April 23, 2014 - Seeking Alpha
Will Today Be the Day the Dow Finally Does It? 9:11 p.m. April 23, 2014 - InvestorPlace.com
Biogen Q1, Guidance Strong, But Stock Slips 5:46 p.m. April 23, 2014 - Investors Business Daily
Why Biogen (BIIB) Stock Is Down Today 1:55 p.m. April 23, 2014 - TheStreet.com
Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog 1:40 p.m. April 23, 2014 - Zacks.com
10-Q: BIOGEN IDEC INC. 1:26 p.m. April 23, 2014 - Edgar Online - (EDG = 10Q, 10K)
Biogen Q1 Sales Beat Street, Guidance Strong 9:11 a.m. April 23, 2014 - Investors Business Daily
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership 8:01 a.m. April 24, 2014 - BusinessWire - BZX
Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII 8:02 a.m. April 21, 2014 - Marketwire
RBCC Bioprinting Partner Expands Brand Awareness Campaign 4:28 a.m. April 16, 2014 - BusinessWire - BZX
Surveyed European Neurologists Expect to Prescribe Biogen Idec's Tecfidera to 16 Percent of their Diagnosed Relapsing-Remitting Multiple Sclerosis Patients in the Next 12 Months 1:00 p.m. April 15, 2014 - PR Newswire - PRF
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept 8:00 a.m. April 15, 2014 - PR Newswire - PRF
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting 7:30 a.m. April 14, 2014 - BusinessWire - BZX
JPMorgan Chase First Quarter Earnings Falls 20 Percent; FBI Probes Herbalife Business 12:36 a.m. April 14, 2014 - ACCESSWIRE
Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts 9:00 a.m. April 11, 2014 - BusinessWire - BZX
Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer 7:30 a.m. April 10, 2014 - BusinessWire - BZX
Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate(TM) (rFVIIIFc) for haemophilia A 7:06 a.m. April 10, 2014 - Thomson Reuters ONE
Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ (rFVIIIFc) for Hemophilia A 7:00 a.m. April 10, 2014 - BusinessWire - BZX
RBCC and n3D Seek Out Additional Capital 5:00 a.m. April 9, 2014 - BusinessWire - BZX
Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services 8:00 a.m. April 8, 2014 - PR Newswire - PRF
Bioprinting Investment Puts RBCC at Forefront of 3-D Revolution 5:00 a.m. April 3, 2014 - BusinessWire - BZX
Biogen Idec to Report First Quarter 2014 Financial Results on April 23, 2014 4:01 p.m. March 31, 2014 - BusinessWire - BZX
Sobi: US FDA approves Alprolix(TM) 2:05 a.m. March 31, 2014 - GlobeNewswire
Sobi: US FDA approves Alprolix(TM) 2:01 a.m. March 31, 2014 - Thomson Reuters ONE
FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart 6:34 p.m. March 28, 2014 - BusinessWire - BZX
FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart 6:24 p.m. March 28, 2014 - BusinessWire - BZX
Critical Alerts For DirecTV, Biogen Idec, Time Warner, Isis Pharmaceuticals, and DreamWorks Animation Released By InvestorsObserver 9:31 a.m. March 27, 2014 - PR Newswire - PRF
Investors gloss over Biogen earnings miss and focus on MS drug sales 2:23 p.m. April 23, 2014 - blogs.marketwatch.com
Scouring the moonscape for leading stocks 3:01 p.m. April 22, 2014 - The Trading Deck
Apple, Microsoft are not the keys to this week’s news 7:00 a.m. April 22, 2014 - Marek Fuchs
Long view on stocks is best during weak earnings season 6:00 a.m. April 20, 2014 - Wallace Witkowski
Biotech misses out on Nasdaq rally, sinks further into bear ground 4:58 p.m. April 14, 2014 - blogs.marketwatch.com
Herbalife sinks on probe fears; Zoe’s surges on debut 4:36 p.m. April 11, 2014 - Ben Eisen
Stocks fall for 3rd day in row; S&P 500 down for year again: stock market live blog recap 4:11 p.m. April 7, 2014 - blogs.marketwatch.com
Biotech bargain? 11:43 a.m. April 1, 2014 - The Trading Deck
Facebook, Biogen, Cal-Maine are stocks to watch 5:21 a.m. March 31, 2014 - Victor Reklaitis
U.S. stocks end week with losses 7:17 p.m. March 28, 2014 - Anora Mahmudova
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - blogs.marketwatch.com
U.S. stocks fall; Nasdaq skids 1.2% 4:40 p.m. March 24, 2014 - Anora Mahmudova
Biotech has second straight sell-off; sector mutual funds take it on chin 10:40 a.m. March 24, 2014 - blogs.marketwatch.com
First Solar extends winning streak; Symantec plunges 3:06 p.m. March 21, 2014 - Ben Eisen
Investors let air out of biotech amid overheating, pricing concerns 1:42 p.m. March 21, 2014 - blogs.marketwatch.com
U.S. stocks rise; S&P 500 positive for the year 4:39 p.m. March 17, 2014 - Anora Mahmudova
Yahoo gains on Alibaba IPO; Plug Power loses momentum 4:17 p.m. March 17, 2014 - Saumya Vaishampayan
Keurig Green Mountain added to S&P 500 index 9:56 a.m. March 15, 2014 - MarketWatch.com
From every angle, technicals point to richer stocks 2:25 p.m. March 11, 2014 - The Trading Deck
Disappointments? Think Opportunities; Miracle Drug May Be Ailing Gilead: Jim Cramer's Best Blogs 6:00 a.m. April 26, 2014 - TheStreet.com
Amgen Blazed Biotech Trail, Earned 165,233% Reward 5:51 p.m. April 25, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: EBAY, AXP, BIIB 3:59 p.m. April 25, 2014 - TheStreet.com
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog 5:50 p.m. April 24, 2014 - Zacks.com
Gilead, Alexion, Biogen, Or Celgene: 1 Mindboggling Metric Identifies The Best Value! 4:57 p.m. April 24, 2014 - Seeking Alpha
3 Drugs Stocks Dragging The Industry Down 1:03 p.m. April 24, 2014 - TheStreet.com
Stock Market News for April 24, 2014 - Market News 10:06 a.m. April 24, 2014 - Zacks.com
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape 8:49 a.m. April 24, 2014 - Zacks.com
Prothena Corporation plc (PRTA) Worth Watching: Stock Rises 9.5% - Tale of the Tape 8:44 a.m. April 24, 2014 - Zacks.com
Biogen partners with Quintiles to beef up its clinical development processes 8:18 a.m. April 24, 2014 - Seeking Alpha
Biogen Idec Inc. (BIIB): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. April 24, 2014 - Zacks.com
Quintiles, Biogen Idec Announce Comprehensive Clinical Development Partnership 7:01 a.m. April 24, 2014 - benzinga.com
After the Apple Split, Five More Bull Market Stock Splits Needed 6:39 a.m. April 24, 2014 - 247WallSt.com
Biogen Idec's CEO Discusses Q1 2014 Earnings Results - Earnings Call Transcript 10:54 p.m. April 23, 2014 - Seeking Alpha
Will Today Be the Day the Dow Finally Does It? 9:11 p.m. April 23, 2014 - InvestorPlace.com
Biogen Q1, Guidance Strong, But Stock Slips 5:46 p.m. April 23, 2014 - Investors Business Daily
Why Biogen (BIIB) Stock Is Down Today 1:55 p.m. April 23, 2014 - TheStreet.com
Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog 1:40 p.m. April 23, 2014 - Zacks.com
10-Q: BIOGEN IDEC INC. 1:26 p.m. April 23, 2014 - Edgar Online - (EDG = 10Q, 10K)
Biogen Q1 Sales Beat Street, Guidance Strong 9:11 a.m. April 23, 2014 - Investors Business Daily
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership 8:01 a.m. April 24, 2014 - BusinessWire - BZX
Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII 8:02 a.m. April 21, 2014 - Marketwire
RBCC Bioprinting Partner Expands Brand Awareness Campaign 4:28 a.m. April 16, 2014 - BusinessWire - BZX
Surveyed European Neurologists Expect to Prescribe Biogen Idec's Tecfidera to 16 Percent of their Diagnosed Relapsing-Remitting Multiple Sclerosis Patients in the Next 12 Months 1:00 p.m. April 15, 2014 - PR Newswire - PRF
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept 8:00 a.m. April 15, 2014 - PR Newswire - PRF
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting 7:30 a.m. April 14, 2014 - BusinessWire - BZX
JPMorgan Chase First Quarter Earnings Falls 20 Percent; FBI Probes Herbalife Business 12:36 a.m. April 14, 2014 - ACCESSWIRE
Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts 9:00 a.m. April 11, 2014 - BusinessWire - BZX
Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer 7:30 a.m. April 10, 2014 - BusinessWire - BZX
Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate(TM) (rFVIIIFc) for haemophilia A 7:06 a.m. April 10, 2014 - Thomson Reuters ONE
Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ (rFVIIIFc) for Hemophilia A 7:00 a.m. April 10, 2014 - BusinessWire - BZX
RBCC and n3D Seek Out Additional Capital 5:00 a.m. April 9, 2014 - BusinessWire - BZX
Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services 8:00 a.m. April 8, 2014 - PR Newswire - PRF
Bioprinting Investment Puts RBCC at Forefront of 3-D Revolution 5:00 a.m. April 3, 2014 - BusinessWire - BZX
Biogen Idec to Report First Quarter 2014 Financial Results on April 23, 2014 4:01 p.m. March 31, 2014 - BusinessWire - BZX
Sobi: US FDA approves Alprolix(TM) 2:05 a.m. March 31, 2014 - GlobeNewswire
Sobi: US FDA approves Alprolix(TM) 2:01 a.m. March 31, 2014 - Thomson Reuters ONE
FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart 6:34 p.m. March 28, 2014 - BusinessWire - BZX
FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart 6:24 p.m. March 28, 2014 - BusinessWire - BZX
Critical Alerts For DirecTV, Biogen Idec, Time Warner, Isis Pharmaceuticals, and DreamWorks Animation Released By InvestorsObserver 9:31 a.m. March 27, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼